Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3877174 | 0.95 | KDM4E (0.49) | KDM4EFFAR1ACHESLC6A4PPARG | |
| SCHEMBL3866649 | 0.86 | KDM4E (0.49) | KDM4EFFAR1ACHESLC6A4PPARG | |
| Dimethylformamide SCHEMBL6715442 | 0.85 | KDM4E (0.43) | KDM4EFFAR1PPARGPPARDMEN1 | |
| Hydrochloric Acid SCHEMBL3863877 | 0.85 | KDM4E (0.48) | KDM4EFFAR1ACHESLC6A4PPARG | |
| SCHEMBL3864605 | 0.80 | NPSR1 (0.48) | ACHESLC6A4MEN1NPC1RAB9A | |
| SCHEMBL3874630 | 0.80 | KDM4E (0.47) | KDM4EFFAR1PPARGPPARDMEN1 | |
| SCHEMBL3862379 | 0.79 | ACHE (0.51) | KDM4EFFAR1ACHESLC6A4PPARG | |
| SCHEMBL3864683 | 0.78 | ACHE (0.63) | KDM4EFFAR1ACHESLC6A4PPARG | |
| Hydrochloric Acid SCHEMBL3864505 | 0.77 | ACHE (0.62) | KDM4EFFAR1ACHESLC6A4 | |
| Hydrochloric Acid SCHEMBL3864088 | 0.77 | ACHE (0.62) | KDM4EFFAR1ACHESLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067981-A1 | Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants | SANKYO COMPANY, LIMITED (JP) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067981-A1 | Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants | ACHE, BACE1, CHRNA6 | KDM4E 1990/4885FFAR1 2437/4885ACHE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.